Inhibitory effect of 6-hydroxy-7-methoxychroman-2-carboxylic acid phenylamide on nitric oxide and interleukin-6 production in macrophages

6-Hydroxy-7-methoxychroman-2-carboxylic acid phenylamide (CP compound) is a novel chemically synthetic compound with vitamin E-like chemical structure. In the present study, the CP compound was discovered to inhibit nitric oxide (NO) and interleukin (IL)-6 productions in lipopolysaccharide (LPS)-sti...

Full description

Saved in:
Bibliographic Details
Published in:Life sciences (1973) 2005-11, Vol.77 (25), p.3242-3257
Main Authors: Rak Min, Kyung, Lee, Heesoon, Hak Kim, Byung, Chung, EunYong, Min Cho, Sung, Kim, Youngsoo
Format: Article
Language:English
Subjects:
Activator protein-1
Animals
Cell Line
Cell Survival - drug effects
Chromans - pharmacology
Down-Regulation
Interleukin-6
Interleukin-6 - biosynthesis
Lipopolysaccharides - pharmacology
Macrophages, Peritoneal - drug effects
Macrophages, Peritoneal - enzymology
Macrophages, Peritoneal - metabolism
Male
Mice
Mice, Inbred ICR
NF-kappa B - metabolism
Nitric oxide
Nitric Oxide - biosynthesis
Nitric Oxide Synthase - biosynthesis
Nitric Oxide Synthase Type II
Nuclear factor-κB
Transcription Factor AP-1 - metabolism
Vitamin E analog
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:6-Hydroxy-7-methoxychroman-2-carboxylic acid phenylamide (CP compound) is a novel chemically synthetic compound with vitamin E-like chemical structure. In the present study, the CP compound was discovered to inhibit nitric oxide (NO) and interleukin (IL)-6 productions in lipopolysaccharide (LPS)-stimulated macrophages. Further, CP compound attenuated LPS-induced synthesis of mRNA and protein levels of inducible NO synthase (iNOS), in parallel, and inhibited iNOS promoter activity. In the similar way, CP compound inhibited LPS-induced synthesis of IL-6 transcript but also IL-6 promoter activity. These results indicate that CP compound could down-regulate LPS-induced iNOS and IL-6 expression at the transcription step. As a mechanism of the anti-inflammatory action shown by CP compound, suppression of LPS-induced activation of both nuclear factor-κB (NF-κB) and activator protein-1 (AP-1) has been documented. Finally, CP compound could provide an invaluable tool to investigate LPS-induced NF-κB and AP-1 activation, in addition to its therapeutic potential in NO- and IL-6-associated inflammatory diseases.
ISSN:0024-3205
1879-0631
DOI:10.1016/j.lfs.2005.05.046